Loading page
Loading page
Loading substance route
Classified as habit-forming. Its relatively low efficacy at blocking dopamine reuptake despite high binding affinity led to its investigation as a possible substitute drug for treatment of stimulant abuse, suggesting potentially lower reinforcing effects compared to other stimulants.
Visual and auditory hallucinations are listed among possible effects.
4-Methylmethylphenidate emerged on the designer stimulant market in mid-2015, appearing shortly after regulatory actions in the United Kingdom restricted ethylphenidate and other phenidate compounds. Its commercial availability as an unscheduled research chemical proved exceptionally brief, lasting…
Designated as a Temporary Class Drug beginning in June 2015 following its unapproved sale as a designer drug. This classification prohibits importation, exportation, production, and supply of the substance.
Not explicitly scheduled at the federal level, but may be treated as a controlled substance under the Federal Analogue Act when intended for human consumption due to its structural relationship to methylphenidate. A September 2023 DEA proposal to place ethylphenidate into Schedule I would encompass its positional isomers, including this compound.